1. Home
  2. MGNX vs UNB Comparison

MGNX vs UNB Comparison

Compare MGNX & UNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNX
  • UNB
  • Stock Information
  • Founded
  • MGNX 2000
  • UNB 1891
  • Country
  • MGNX United States
  • UNB United States
  • Employees
  • MGNX N/A
  • UNB N/A
  • Industry
  • MGNX Biotechnology: Pharmaceutical Preparations
  • UNB Major Banks
  • Sector
  • MGNX Health Care
  • UNB Finance
  • Exchange
  • MGNX Nasdaq
  • UNB Nasdaq
  • Market Cap
  • MGNX 99.7M
  • UNB 117.7M
  • IPO Year
  • MGNX 2013
  • UNB 1998
  • Fundamental
  • Price
  • MGNX $1.53
  • UNB $25.83
  • Analyst Decision
  • MGNX Hold
  • UNB
  • Analyst Count
  • MGNX 6
  • UNB 0
  • Target Price
  • MGNX $3.20
  • UNB N/A
  • AVG Volume (30 Days)
  • MGNX 1.0M
  • UNB 6.0K
  • Earning Date
  • MGNX 11-04-2025
  • UNB 10-15-2025
  • Dividend Yield
  • MGNX N/A
  • UNB 5.56%
  • EPS Growth
  • MGNX N/A
  • UNB N/A
  • EPS
  • MGNX N/A
  • UNB 2.01
  • Revenue
  • MGNX $165,495,000.00
  • UNB $48,950,000.00
  • Revenue This Year
  • MGNX N/A
  • UNB N/A
  • Revenue Next Year
  • MGNX N/A
  • UNB N/A
  • P/E Ratio
  • MGNX N/A
  • UNB $12.93
  • Revenue Growth
  • MGNX 303.47
  • UNB 2.99
  • 52 Week Low
  • MGNX $0.99
  • UNB $24.57
  • 52 Week High
  • MGNX $5.10
  • UNB $37.70
  • Technical
  • Relative Strength Index (RSI)
  • MGNX 43.37
  • UNB 44.19
  • Support Level
  • MGNX $1.46
  • UNB $25.72
  • Resistance Level
  • MGNX $1.77
  • UNB $26.34
  • Average True Range (ATR)
  • MGNX 0.15
  • UNB 0.30
  • MACD
  • MGNX -0.04
  • UNB 0.03
  • Stochastic Oscillator
  • MGNX 9.21
  • UNB 13.41

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About UNB Union Bankshares Inc.

Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group.

Share on Social Networks: